Mealey's (September 15, 2015, 12:02 PM EDT) -- SAN DIEGO — The California federal judge overseeing the incretin mimetic multidistrict litigation on Sept. 11 ordered the return of inadvertently disclosed data from defendant Novo Nordisk Inc.’s LEADER clinical trial, saying it should be protected until the study is completed and published (In Re: Incretin-Based Therapies Products Liability Litigation, MDL Docket No. 2452, No. 13-md-2452, S.D. Calif.)....